. Author manuscript; available in PMC: 2013 Apr 1.

Published in final edited form as: Curr Opin Immunol. 2012 Jan 9;24(2):207–212. doi: 10.1016/j.coi.2011.12.009

Table 1.

PD-1 and B7-H1/PD-L1 blocking agents currently in clinical testing^a

	Target Molecule
Source	PD-1	B7-H1/PD-L1
Amplimmune Inc./GlaxoSmithKline	AMP-224 (B7-DC/IgG1 fusion protein)	N/A
Bristol-Myers Squibb	MDX-1106/BMS-936558/ONO-4538 (fully human IgG4 mAb)	MDX-1105/BMS-936559 (fully human IgG4 mAb)
CureTech/Teva	CT-011 (humanized IgG1 mAb)	N/A
Merck	MK-3475 (humanized IgG4 mAb)	N/A

^(a)

Information about clinical trials can be found at ClinicalTrials.gov, http://www.clinicaltrials.gov.